Stocks · News reference

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5

Aug 28, 2026, 10:50 AMBenzinga Newsdesk

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 28, 2026, 10:50 AM
Checked: Aug 28, 2026, 10:50 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 1, 2026, 12:39 PMBenzinga Newsdesk
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center
RNXT
BenzingaAug 25, 2026, 5:26 PMBenzinga Newsdesk
RenovoRx shares are trading higher after the company announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.
RNXT
BenzingaAug 25, 2026, 5:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report
AIXC AMIX CDT CELGR JUNS